Real-world time to discontinuation of first-li... - CLL Support
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
You need to be a member of this community to see this post.
Read more about...
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Real-world incidence and prevention of tumor lysis syndrome (TLS) in chronic lymphocytic leukemia (CLL) treated with venetoclax. From MSK
A few members who have been recommended ventoclax/Venclexta treatment, have posted about their...
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters
Several of us have reported our CLL symptoms have come roaring back after discontinuing...
"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
Encouraging news in this abstract from CLL/SLL researchers at the Northwestern Memorial Hospital,...
Debulking Eliminates Need for Hospitalization Prior to Initiating Venetoclax Therapy in untreated CLL pts
This is a report of Phase 3 study NCT03406156.
Due to the rapid induction of cell death caused by...
Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some...
Related Posts
- Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lym
Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax- FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
